Dr. Loh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1120 Veterans Blvd
South San Francisco, CA 94080Phone+1 650-244-2868
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1988 - 1989
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1984 - 1987
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1981 - 1984
- Stanford University School of MedicineClass of 1981
Certifications & Licensure
- CA State Medical License 1982 - 2024
- PA State Medical License 1989 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2000 Jul 01
Publications & Presentations
PubMed
- 22 citationsRilotumumab Exposure-Response Relationship in Patients With Advanced or Metastatic Gastric CancerSameer Doshi, Per Olsson Gisleskog, Yilong Zhang, Min Zhu, Kelly S. Oliner
Clinical Cancer Research. 2015-02-24 - 33 citationsExposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expressionMin Zhu, Rui Tang, Sameer Doshi, Kelly S. Oliner, Sarita Dubey
British Journal of Cancer. 2015-02-03 - 88 citationsRandomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Swieboda-Sadlej, Niall C. Tebbutt
Clinical Cancer Research. 2014-08-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: